No. Psilocybin is not federally legal today. It remains a Schedule I controlled substance, and a bill introduced on October 29, 2026 would not legalize it. What to do first: check the federal rule as it stands now, and treat the new bill as a proposal until Congress passes it.
The bill would instead require federal health officials to re-evaluate how psilocybin is scheduled. Marijuana Moment reports that psilocybin must be re-evaluated within two years. The bill does not by itself make psilocybin legal; it changes how its schedule would be decided.
Is psilocybin legal under federal law right now?
No. Under current federal law (21 CFR 1308.11), psilocybin is a Schedule I controlled substance. The NCCIH psilocybin guide from the National Institutes of Health says the Drug Enforcement Administration “lists psilocybin as a Schedule 1 controlled substance and possessing it is illegal at the Federal level in the United States.”
Schedule I is defined by statute as a substance with “a high potential for abuse,” “no currently accepted medical use in treatment,” and “lacking accepted safety for use under medical supervision.” The JAAPL article on psilocybin as medicine notes that psilocybin has been a Schedule I substance since 1971.
Will psilocybin become legal now?
Not from this bill. Rep. Steve Cohen (D-TN) introduced the Public Health and Research Reforms in Controlled Substances Act (of 2026) on October 29, 2026. His office’s press release on the bill says it would first review about 30 substances, including psilocybin and ibogaine, and states: “None of these would be descheduled.”
Marijuana Moment’s report on the bill names the priority group as psilocybin, LSD, MDMA, DMT and ibogaine. Those five would have to be re-evaluated within two years. For psilocybin, LSD, MDMA, DMT and ibogaine, the bill changes the review process, and the release says none of the first-evaluated substances would be descheduled.
| Part of the bill | What the sources say it does |
|---|---|
| Psilocybin’s status today | Schedule I. The bill does not change it by itself. |
| Re-evaluation | Psilocybin, LSD, MDMA, DMT and ibogaine must be re-evaluated within two years. |
| Descheduling | “None of these would be descheduled,” according to the release on the first-evaluated substances. |
| Who decides the schedule | Core scheduling authority moves from the Justice Department, attorney general and DEA to HHS. |
| How drugs are rated | Two scales: one for substance use disorder and public-health threat (Schedules I-IV), and one for medical efficacy (Schedules A-E). Example: “Schedule IA.” |
| Mandatory minimums | Weight-based drug mandatory minimum sentences are eliminated. |
What do the two-year deadline and “default placement” mean?
Under the bill, health officials must re-evaluate psilocybin within two years. The bill also replaces the current eight-factor analysis with a 14-factor review, and a federal committee of 15 to 25 members would run the multi-criteria analysis, according to Marijuana Moment.
If health officials miss the two-year deadline, the bill gives them new default placements. A default placement is the schedule that applies automatically when the review is not finished in time. For the exact placements, read the bill text once it is available from the sponsor’s office.
What happens to weight-based mandatory minimums?
The bill would eliminate weight-based drug mandatory minimum sentences, which tie a minimum prison term to the weight of the drug involved. It would also allow resentencing for people whose offenses would carry lower penalties under the new system, and it directs the U.S. Sentencing Commission to revise its guidelines, with retroactivity, according to the release and Marijuana Moment. This is a proposed change. It is not law.
Where is the bill now?
- The bill was introduced on October 29, 2026.
- No committee action, hearing, vote or passage is reported.
- No cosponsors are named in the release, and it gives no bill number. Ask Rep. Cohen’s office for the number and the text.
- Cohen sits on the House Judiciary Committee and is retiring at the end of 2026, according to Marijuana Moment.
- The release names MAPS, Students for Sensible Drug Policy, Drug Policy Alliance and NORML as endorsing groups.
Cohen said: “A thoughtful review of national drug policy is long overdue.” Introducing a bill does not change any law. For how bills, statutes and rules differ, see statute regulation rule or guidance.
Is federal law the same as state law?
No. Federal and state law are separate. The JAAPL article says psilocybin “remains illegal on the federal level despite increasing efforts to decriminalize it at the state and local levels.” Some states and cities have decriminalized it, and that does not change the federal rule. For one state’s rules, see Is Psilocybin Legal in Oregon.
Is psilocybin safe, and is it addictive?
The NCCIH guide lists these adverse effects of psilocybin:
| Area | What NCCIH lists |
|---|---|
| Body | Increased blood pressure and heart rate, headache, nausea, dizziness, fatigue, poor sleep |
| Mind | Anxiety, paranoia, persistent psychosis, hallucinations |
| Experience | Some people report “bad trips,” with extreme fear, confusion or panic |
| Contamination | Adulteration with fentanyl is possible |
| Look-alikes | Some poisonous mushrooms look like psilocybin mushrooms, and confusing them could lead to fatal poisoning |
| Very high amounts | Psilocybin can cause death |
NCCIH also says psilocybin is not safe for people with psychotic conditions such as schizophrenia, schizoaffective disorder, or severe forms of bipolar disorder and borderline personality disorder. It says it is not clear whether microdosing is safe or effective.
On addiction, the JAAPL article says the physical and psychological dependence potential of psilocybin “has been evaluated to be low despite this classification.”
Where does psilocybin come from?
The MOST Policy Initiative’s note on psilocybin decriminalization describes it as “a naturally occurring compound found in certain mushrooms that influences mood and perception.” NCCIH says nonmedical use refers to mushrooms containing psilocybin, and that synthetic production “is complicated and expensive.”
Is psilocybin being studied as a therapy?
Yes. NCCIH says research interest in psychedelic drugs for conditions including depression, anxiety, PTSD and addiction has been growing. The FDA granted breakthrough therapy designation to psilocybin-assisted psychotherapy for major depressive disorder in 2019 and for treatment-resistant depression in 2018.
The JAAPL article describes psilocybin as a promising potential treatment in preliminary research. MOST says no psilocybin treatment has been approved, and it describes an April 2026 executive order as directing federal agencies to fast-track review of psilocybin once the FDA has approved it.
Can I legally buy psilocybin spores?
Spores are a separate question from the mushrooms themselves. Wikipedia’s legal status of psilocybin mushrooms article says the spores “do not contain the drugs, and are legal to possess in many areas.” Whether spores are federally lawful is a point to confirm with a licensed lawyer.
State rules vary. The same Wikipedia article says California, Georgia and Idaho have criminalized possession of psilocybin mushroom spores. A licensed lawyer in your state can tell you how the rules apply to you.
What to check before you act
- Ask Rep. Cohen’s office for the bill number and text.
- Watch for committee action. None is reported yet.
- Check your state’s rules separately. Federal law does not change them.
- If you face a charge or a specific question, talk with a licensed lawyer in your state.
By LegalHelpOnline.org Legal Research & Editorial Team